Drug Profile


Alternative Names: AZD-3480; RJR-1734; TC 01734; TC-1734; TC-1734-112

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator R. J. Reynolds Tobacco Company; Targacept
  • Developer AstraZeneca; Targacept
  • Class Amines; Neuroprotectants; Nootropics; Pyridines; Small molecules
  • Mechanism of Action Alpha4 beta2 nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 14 Jul 2014 Discontinued - Phase-II for Alzheimer's disease in USA, Czech Republic, Romania, Slovakia and Ukraine (PO)
  • 29 Apr 2013 Targacept completes enrolment in its phase IIb trial for Alzheimer’s disease in USA, Czech Republic, Romania, Slovakia & Ukraine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top